Jay Feingold News Today

Financing round led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates, and Lightstone Ventures...

• Prioritized pipeline to focus on most advanced programs while maintaining financial flexibility to pursue business development opportunities • Appointed Rachel Humphrey, M.D., a... | August 15, 2022

/PRNewswire/ -- Biosion, Inc., a global R&D stage biotechnology company, today announced that Biosion and Pyxis Oncology (NASDAQ: PYXS) have entered into an...

As a barometer of the rude health biotechs continue to find themselves in on Wall Street, Big Pharma-backed oncology player Pyxis Oncology is upping its IPO.

ZYNLONTA™ LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCLSubgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65LAUS...

ZYNLONTA LOTIS-2 updated data includes median duration of response of 13.4 months in heavily pre-treated patients with relapsed or refractory DLBCL Subgroup analyses include patients with double-

(1) Camidanlumab tesirine (Cami) demonstrated anti-tumoral activity response rate in 86% of Hodgkin lymphoma patients at dose currently being evaluated in ongoing pivotal Phase 2 trial ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of the Phase 1 clinical trial of camidanlumab tesirine (Cami), an anti-CD25 ADC, in patients...

Published: May 12, 2021   ZYNLONTA™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCL   LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of L...

Recent FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) was based on data from LOTIS-2ZYNLONTA™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCLLAUSANNE, Switzerland--(BUSINES...

ADC Therapeutics SA: ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology ZYNLONTA demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCL ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, to...